Lilly Drug Removes Bad Alzheimer’s Protein in Six Months (1)

Eli Lilly & Co. on Wednesday presented promising results on another experimental Alzheimer’s drug -- just a day after rival Eisai Co. reported data on a treatment that looks poised to become the first therapy to unambiguously slow the brain disease.

In a study of 148 early Alzheimer’s patients, Lilly reported that donanemab lowered levels of a bad protein in the brain called amyloid by 65% after six months of treatment. In nearly 38% of the patients, amyloid that had built up for years was fully cleared in that period, according to results presented at the Clinical Trials on Alzheimer’s ...